Statement of Clinical Relevance
- •We report a case of ONJ with pembrolizumab, a rare yet possibly emerging complication. The number of patients using pembrolizumab will likely continue to increase. We document this instance to better inform dental treatment around cancer patients undergoing pembrolizumab therapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
December 28,
2022
Received in revised form:
December 20,
2022
Received:
October 18,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
